Indication
Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Loading your page…
Loading your page…
Dermatitis, Atopic
Marketing Authorisation Holder: Almirall, S.A.
EMA Authorisation: 16/11/2023
INN: lebrikizumab
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ebglyss: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.